Gustavo Daniel Frechtel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gustavo Daniel Frechtel has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Gloria Edith Cerrone
Laboratorio de Genética y Metabolismo CONICET‐Universidad de Buenos Aires, Instituto de Inmunología, Genética y Metabolismo (INIGEM) Buenos Aires Argentina
7 shared publications - Andrea Liliana Millán
Laboratorio de Genética y Metabolismo CONICET‐Universidad de Buenos Aires, Instituto de Inmunología, Genética y Metabolismo (INIGEM) Buenos Aires Argentina
5 shared publications - Andrea Elena Iglesias Molli
Laboratorio de Genética y Metabolismo CONICET‐Universidad de Buenos Aires, Instituto de Inmunología, Genética y Metabolismo (INIGEM) Buenos Aires Argentina
3 shared publications - Héctor Manuel Targovnik
Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología, Biotecnología y Genética/Cátedra de Genética. Buenos Aires, Argentina
2 shared publications - Mariela Caputo
Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Centro de Referencia en Identificación Humana ‐ Servicio de Huellas Digitales Genéticas, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) Buenos Aires Argentina
2 shared publications Alberto Penas‐Steinhardt
University Institute of Health Sciences, Barcelo Foundation, Buenos Aires, Argentina
1 shared publication
Latest Publications
- 27 September 2026
- Published by Wiley in Pediatric Obesity
- Vol. 21 (10) , e70153
Mitochondrial Dysfunction Markers in Paediatric Obesity: DNA Content and Oxidation Damage
Background: Childhood obesity increases chronic disease risk. Mitochondrial dysfunction, reflected by altered mitochondrial DNA (mtDNA) content and oxidative damage, has been implicated in obesity‐related metabolic disorders, but paediatric data remain scarce. Objective: To evaluate mtDNA content and oxidation in children with obesity, stratified as metabolically healthy (MHO) or unhealthy (MUO), compared with peers with normal weight (NW). Methods: Cross‐sectional study of 114 children aged 7–14 years: NW ( n = 37), MHO ( n = 40) and MUO ( n = 37). mtDNA content was measured by qPCR, and oxidative damage as 8‐oxoguanine by FPG‐qPCR. Analyses included Student's t ‐test, one‐way ANOVA with Tukey HSD, Pearson's χ 2 and linear regression adjusted for age, sex and Tanner stage. Results: Children with obesity showed elevated cardiometabolic risk, lower HDL‐c, insulin resistance (IR), inflammation and significantly lower mtDNA content (−30.9%; p = 0.004) compared with NW, with no differences between MHO and MUO. Higher BMI was independently associated with lower mtDNA content (−3.72% per 1 kg/m 2 ; p = 0.003), consistent across pubertal stages. In a multivariable model of metabolic syndrome components, HDL‐c was independently associated with mtDNA content ( β = 0.33; p = 0.016). Lower mtDNA content was also associated with IR and higher hs‐CRP ( B = −0.13; p = 0.028). mtDNA oxidation showed only a non‐significant trend in obesity. Conclusions: Lower mtDNA content was detectable in MHO and independently associated with HDL‐c and subclinical inflammation. The absence of MHO–MUO differences suggests that chronic inflammation and IR, common to both phenotypes, may be the main factors associated with mtDNA variation at this age.
- 27 September 2026
- Published by Wiley in Pediatric Obesity
- Vol. 21 (10) , e70153
Mitochondrial Dysfunction Markers in Paediatric Obesity: DNA Content and Oxidation Damage
Background: Childhood obesity increases chronic disease risk. Mitochondrial dysfunction, reflected by altered mitochondrial DNA (mtDNA) content and oxidative damage, has been implicated in obesity‐related metabolic disorders, but paediatric data remain scarce. Objective: To evaluate mtDNA content and oxidation in children with obesity, stratified as metabolically healthy (MHO) or unhealthy (MUO), compared with peers with normal weight (NW). Methods: Cross‐sectional study of 114 children aged 7–14 years: NW ( n = 37), MHO ( n = 40) and MUO ( n = 37). mtDNA content was measured by qPCR, and oxidative damage as 8‐oxoguanine by FPG‐qPCR. Analyses included Student's t ‐test, one‐way ANOVA with Tukey HSD, Pearson's χ 2 and linear regression adjusted for age, sex and Tanner stage. Results: Children with obesity showed elevated cardiometabolic risk, lower HDL‐c, insulin resistance (IR), inflammation and significantly lower mtDNA content (−30.9%; p = 0.004) compared with NW, with no differences between MHO and MUO. Higher BMI was independently associated with lower mtDNA content (−3.72% per 1 kg/m 2 ; p = 0.003), consistent across pubertal stages. In a multivariable model of metabolic syndrome components, HDL‐c was independently associated with mtDNA content ( β = 0.33; p = 0.016). Lower mtDNA content was also associated with IR and higher hs‐CRP ( B = −0.13; p = 0.028). mtDNA oxidation showed only a non‐significant trend in obesity. Conclusions: Lower mtDNA content was detectable in MHO and independently associated with HDL‐c and subclinical inflammation. The absence of MHO–MUO differences suggests that chronic inflammation and IR, common to both phenotypes, may be the main factors associated with mtDNA variation at this age.
- Open Access
- 30 May 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (9) , 2526-2534
Advancing therapy in people with suboptimally controlled basal insulin‐treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries
Aims: This subanalysis of the SoliMix trial assessed the efficacy and safety of advancing basal insulin (BI) therapy with iGlarLixi versus BIAsp 30 in people with type 2 diabetes (T2D) living in Latin American (LATAM) countries, i.e. Argentina and Mexico ( N = 160). Materials and Methods: SoliMix (EudraCT: 2017‐003370‐13) was a 26‐week, open‐label, multicentre study, where adults with T2D suboptimally controlled with BI plus one or two oral glucose‐lowering drugs and glycated haemoglobin (HbA1c) ≥7.5% to ≤10% were randomized to once‐daily iGlarLixi or twice‐daily BIAsp 30. Primary efficacy endpoints were non‐inferiority in HbA1c reduction (margin 0.3%) or superiority in body weight change for iGlarLixi versus BIAsp 30. Results: Both primary efficacy endpoints were met in the LATAM region. After 26 weeks, HbA1c was reduced by 1.8% with iGlarLixi and 1.4% with BIAsp 30, meeting non‐inferiority [least squares mean difference −0.47% (95% confidence interval: −0.82, −0.11); p < .001]. iGlarLixi was superior to BIAsp 30 for body weight change [least squares mean difference −1.27% (95% confidence interval: −2.41, −0.14); p = .028]. iGlarLixi was also superior to BIAsp 30 for HbA1c reduction ( p = .010). A greater proportion of participants achieved HbA1c <7% without weight gain and HbA1c <7% without weight gain and without hypoglycaemia with iGlarLixi versus BIAsp 30. Incidence and rates of American Diabetes Association Level 1 and 2 hypoglycaemia were lower with iGlarLixi versus BIAsp 30. Conclusions: Once‐daily iGlarLixi provided better glycaemic control with weight benefit and less hypoglycaemia than twice‐daily premix BIAsp 30. iGlarLixi may be a favourable alternative to premix BIAsp 30 in people with suboptimally controlled T2D to advance BI therapy in the LATAM region.
- 30 May 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (9) , 2526-2534
Open AccessAdvancing therapy in people with suboptimally controlled basal insulin‐treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries
Aims: This subanalysis of the SoliMix trial assessed the efficacy and safety of advancing basal insulin (BI) therapy with iGlarLixi versus BIAsp 30 in people with type 2 diabetes (T2D) living in Latin American (LATAM) countries, i.e. Argentina and Mexico ( N = 160). Materials and Methods: SoliMix (EudraCT: 2017‐003370‐13) was a 26‐week, open‐label, multicentre study, where adults with T2D suboptimally controlled with BI plus one or two oral glucose‐lowering drugs and glycated haemoglobin (HbA1c) ≥7.5% to ≤10% were randomized to once‐daily iGlarLixi or twice‐daily BIAsp 30. Primary efficacy endpoints were non‐inferiority in HbA1c reduction (margin 0.3%) or superiority in body weight change for iGlarLixi versus BIAsp 30. Results: Both primary efficacy endpoints were met in the LATAM region. After 26 weeks, HbA1c was reduced by 1.8% with iGlarLixi and 1.4% with BIAsp 30, meeting non‐inferiority [least squares mean difference −0.47% (95% confidence interval: −0.82, −0.11); p < .001]. iGlarLixi was superior to BIAsp 30 for body weight change [least squares mean difference −1.27% (95% confidence interval: −2.41, −0.14); p = .028]. iGlarLixi was also superior to BIAsp 30 for HbA1c reduction ( p = .010). A greater proportion of participants achieved HbA1c <7% without weight gain and HbA1c <7% without weight gain and without hypoglycaemia with iGlarLixi versus BIAsp 30. Incidence and rates of American Diabetes Association Level 1 and 2 hypoglycaemia were lower with iGlarLixi versus BIAsp 30. Conclusions: Once‐daily iGlarLixi provided better glycaemic control with weight benefit and less hypoglycaemia than twice‐daily premix BIAsp 30. iGlarLixi may be a favourable alternative to premix BIAsp 30 in people with suboptimally controlled T2D to advance BI therapy in the LATAM region.
- Open Access
- 14 May 2021
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 12
Telomere Length Differently Associated to Obesity and Hyperandrogenism in Women With Polycystic Ovary Syndrome
Background: Polycystic Ovary Syndrome (PCOS) often present metabolic disorders and hyperandrogenism (HA), facts that may influence the telomere length (TL). Aims: To compare the absolute TL (aTL) between women with PCOS and control women, and their association with the presence of obesity and HA parameters. Materials and methods: The PCOS group included 170 unrelated women outpatients and the control group, 64 unrelated donor women. Anthropometric, biochemical-clinical parameters and androgen profile were determined. The PCOS patients were divided accordingly to the presence of obesity and androgenic condition. The aTL was determined from peripheral blood leukocytes by Real Time quantitative PCR. Results: Women with PCOS exhibited a significantly longer aTL than controls after age adjustment (p=0.001). A stepwise multivariate linear regression in PCOS women, showed that WC (waist circumference) contributed negatively (b=-0.17) while testosterone levels contributed positively (b=7.24) to aTL. The non-Obese PCOS (noOB-PCOS) presented the longest aTL when compared to controls (p=0.001). Meanwhile, the aTL was significantly higher in the hyperandrogenic PCOS phenotype (HA-PCOS) than in the controls (p=0.001) and non hyperandrogenic PCOS phenotype (NHA-PCOS) (p=0.04). Interestingly, when considering obesity and HA parameters in PCOS, HA exerts the major effect over the aTL as non-obese HA exhibited the lengthiest aTL (23.9 ± 13.13 Kbp). Conversely, the obese NHA patients showed the shortest aTL (16.5 ± 10.59 Kbp). Conclusions: Whilst a shorter aTL could be related to the presence of obesity, a longer aTL would be associated with HA phenotype. These findings suggest a balance between the effect produced by the different metabolic and hormonal components, in PCOS women.
- 14 May 2021
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 12
Open AccessTelomere Length Differently Associated to Obesity and Hyperandrogenism in Women With Polycystic Ovary Syndrome
Background: Polycystic Ovary Syndrome (PCOS) often present metabolic disorders and hyperandrogenism (HA), facts that may influence the telomere length (TL). Aims: To compare the absolute TL (aTL) between women with PCOS and control women, and their association with the presence of obesity and HA parameters. Materials and methods: The PCOS group included 170 unrelated women outpatients and the control group, 64 unrelated donor women. Anthropometric, biochemical-clinical parameters and androgen profile were determined. The PCOS patients were divided accordingly to the presence of obesity and androgenic condition. The aTL was determined from peripheral blood leukocytes by Real Time quantitative PCR. Results: Women with PCOS exhibited a significantly longer aTL than controls after age adjustment (p=0.001). A stepwise multivariate linear regression in PCOS women, showed that WC (waist circumference) contributed negatively (b=-0.17) while testosterone levels contributed positively (b=7.24) to aTL. The non-Obese PCOS (noOB-PCOS) presented the longest aTL when compared to controls (p=0.001). Meanwhile, the aTL was significantly higher in the hyperandrogenic PCOS phenotype (HA-PCOS) than in the controls (p=0.001) and non hyperandrogenic PCOS phenotype (NHA-PCOS) (p=0.04). Interestingly, when considering obesity and HA parameters in PCOS, HA exerts the major effect over the aTL as non-obese HA exhibited the lengthiest aTL (23.9 ± 13.13 Kbp). Conversely, the obese NHA patients showed the shortest aTL (16.5 ± 10.59 Kbp). Conclusions: Whilst a shorter aTL could be related to the presence of obesity, a longer aTL would be associated with HA phenotype. These findings suggest a balance between the effect produced by the different metabolic and hormonal components, in PCOS women.
- Open Access
- 21 November 2020
- Published by Editorial Biotecnologica S.R.L. in Revista de la Sociedad Argentina de Diabetes
- Vol. 54 (3Sup) , 88
O3 Impacto de la hiperglucemia y de la relación de la acción terapéutica de la metformina en la longitud de los telómeros
Introducción: la hiperglucemia es uno de los más importantes factores que determinan la producción de estrés oxidativo e inflamación, procesos que pueden acelerar el acortamiento de los telómeros. Objetivos: analizar la longitud telomérica absoluta (LTa) en individuos con niveles de glucosa en ayunas alterada (GAA) en comparación con individuos que presentan niveles normales de glucosa (GAN). Estudiar a partir de un estudio prospectivo controlado, la variación en la LTa en pacientes con DM2 descompensada antes y después del tratamiento. Materiales y métodos: se estudió una población de 246 individuos de ambos sexos, conformada por individuos con obesidad, individuos con DM2 o MODY e individuos controles sanos. Se dividieron en individuos con niveles de glucemia =110 mg/dl y <125 mg/dl (grupo GAA). Además, se dividieron por grupos etarios: menor a 25 años (50Y). Se estudió un subgrupo de 30 pacientes con DM2 de reciente diagnóstico, al inicio (T0) y a los 6 meses (T6) de un tratamiento farmacológico y medidas higiénico-dietéticas, con el objetivo de lograr la compensación metabólica. En ambos estudios se determinaron las variables bioquímico-clínicas de todos los individuos y la LTa por PCR cuantitativa en tiempo real. Los análisis estadísticos se realizaron utilizando el software GraphPad Prism y SPSS.
- 21 November 2020
- Published by Editorial Biotecnologica S.R.L. in Revista de la Sociedad Argentina de Diabetes
- Vol. 54 (3Sup) , 88
Open AccessO3 Impacto de la hiperglucemia y de la relación de la acción terapéutica de la metformina en la longitud de los telómeros
Introducción: la hiperglucemia es uno de los más importantes factores que determinan la producción de estrés oxidativo e inflamación, procesos que pueden acelerar el acortamiento de los telómeros. Objetivos: analizar la longitud telomérica absoluta (LTa) en individuos con niveles de glucosa en ayunas alterada (GAA) en comparación con individuos que presentan niveles normales de glucosa (GAN). Estudiar a partir de un estudio prospectivo controlado, la variación en la LTa en pacientes con DM2 descompensada antes y después del tratamiento. Materiales y métodos: se estudió una población de 246 individuos de ambos sexos, conformada por individuos con obesidad, individuos con DM2 o MODY e individuos controles sanos. Se dividieron en individuos con niveles de glucemia =110 mg/dl y <125 mg/dl (grupo GAA). Además, se dividieron por grupos etarios: menor a 25 años (50Y). Se estudió un subgrupo de 30 pacientes con DM2 de reciente diagnóstico, al inicio (T0) y a los 6 meses (T6) de un tratamiento farmacológico y medidas higiénico-dietéticas, con el objetivo de lograr la compensación metabólica. En ambos estudios se determinaron las variables bioquímico-clínicas de todos los individuos y la LTa por PCR cuantitativa en tiempo real. Los análisis estadísticos se realizaron utilizando el software GraphPad Prism y SPSS.
- Open Access
- 31 October 2020
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 4 (1)
A study to assess the unmet medical needs associated with the use of basal insulin in patients with type 2 diabetes
Aim: To describe in a real‐world setting, the proportion of patients with a symptomatic hypoglycaemic event and the proportion of individuals with type 2 diabetes, who newly or recently initiated with basal insulin, achieving individual or general HbA1c target.Materials and Method: DINAS‐AR was a national prospective observational study to assess the unmet needs in patients with type 2 diabetes treated with basal insulin with or without oral antihyperglycaemic drugs and/or GLP‐1 receptor agonist. The study was conducted at 19 hospitals.Results: A total of 385 uncontrolled patients (≥18 years) who recently initiated basal insulin or who initiated treatment within a year prior to study enrolment entered the study. Outcomes were follow‐up incidence of hypoglycaemic events, change of HbA1C and achievement of HBA1c <7% or individual target. A total of 44 patients (11.9%) reported the occurrence of ≥1 symptomatic hypoglycaemia event(s). HbA1c reductions were greater in patients who had recently initiated treatment with basal insulin (between 15 and 90 days prior to study entry) vs patients who initiated treatment within 1 year. A total of 80 patients (31.6%) achieved individual HbA1c target (or target <7.0%) at Week 24. Furthermore, the proportion of patients achieving this target without symptomatic hypoglycaemia was 26.1% (n = 66). A lower percentage of glycemia target achievement was observed in patients reporting hypoglycaemia (n = 14), 20.6% of all patients reporting hypoglycaemia event(s) vs (n = 66) 35.7% of all patients without hypoglycaemia event reported.Conclusion: In this real‐world study, although the hypoglycaemia rate was not high in adults with type 2 diabetes treated with insulin, there was a lower percentage of patients that achieved glycemic target among those reporting hypoglycaemia events vs patients who did not report them.
- 31 October 2020
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 4 (1)
Open AccessA study to assess the unmet medical needs associated with the use of basal insulin in patients with type 2 diabetes
Aim: To describe in a real‐world setting, the proportion of patients with a symptomatic hypoglycaemic event and the proportion of individuals with type 2 diabetes, who newly or recently initiated with basal insulin, achieving individual or general HbA1c target.Materials and Method: DINAS‐AR was a national prospective observational study to assess the unmet needs in patients with type 2 diabetes treated with basal insulin with or without oral antihyperglycaemic drugs and/or GLP‐1 receptor agonist. The study was conducted at 19 hospitals.Results: A total of 385 uncontrolled patients (≥18 years) who recently initiated basal insulin or who initiated treatment within a year prior to study enrolment entered the study. Outcomes were follow‐up incidence of hypoglycaemic events, change of HbA1C and achievement of HBA1c <7% or individual target. A total of 44 patients (11.9%) reported the occurrence of ≥1 symptomatic hypoglycaemia event(s). HbA1c reductions were greater in patients who had recently initiated treatment with basal insulin (between 15 and 90 days prior to study entry) vs patients who initiated treatment within 1 year. A total of 80 patients (31.6%) achieved individual HbA1c target (or target <7.0%) at Week 24. Furthermore, the proportion of patients achieving this target without symptomatic hypoglycaemia was 26.1% (n = 66). A lower percentage of glycemia target achievement was observed in patients reporting hypoglycaemia (n = 14), 20.6% of all patients reporting hypoglycaemia event(s) vs (n = 66) 35.7% of all patients without hypoglycaemia event reported.Conclusion: In this real‐world study, although the hypoglycaemia rate was not high in adults with type 2 diabetes treated with insulin, there was a lower percentage of patients that achieved glycemic target among those reporting hypoglycaemia events vs patients who did not report them.
- 26 June 2020
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 37 (2) , e3374
MODY patients exhibit shorter telomere length than non‐diabetic subjects
Background: Given the increasing evidence supporting the association between telomere shortening and diabetes, the aim of the present work was to establish whether MODY patients suffer a reduction in telomere lenght (TL) due to oxidative stress produced by chronic hyperglycemia, despite not presenting insulin resistance or inflammation.Methods: We analysed clinical and biochemical parameters in 35 MODY2 and 12 MODY3 patients compared with 48 control subjects. The absolute telomere length (aTL) of peripheral blood leukocytes was measured using the quantitative polymerase chain reaction (qPCR).Results: A significant negative correlation was observed between aTL and age in the whole population, among MODY patients and in each subtype studied, MODY2 and MODY3, which allowed us to validate the method. We found, for the first time, that MODY patients have shorter aTL with respect to non‐diabetic controls (6.49 ± 3.31 kbp vs 11.13 ± 7.82 kbp, p = .006). However, no differences were found between MODY2 and MODY3. In addition, aTL showed a negative correlation with duration of the disease and fasting plasma glucose (FPG) levels in MODY patients in general and also with HbA1c in MODY2 patients in particular.Conclusions: Both MODY2 and MODY3 types present telomere shortening, which, at least partly, responds to HbA1c and FPG levels. These findings suggest comparable mechanisms underlying the attrition of TL. Taken together, our results on aTL in MODY patients may provide a parameter relatively easy and inexpensive to quantify in order to measure the impact of high glucose levels and potentially carry out antidiabetic treatment with stricter targets.
- 26 June 2020
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 37 (2) , e3374
MODY patients exhibit shorter telomere length than non‐diabetic subjects
Background: Given the increasing evidence supporting the association between telomere shortening and diabetes, the aim of the present work was to establish whether MODY patients suffer a reduction in telomere lenght (TL) due to oxidative stress produced by chronic hyperglycemia, despite not presenting insulin resistance or inflammation.Methods: We analysed clinical and biochemical parameters in 35 MODY2 and 12 MODY3 patients compared with 48 control subjects. The absolute telomere length (aTL) of peripheral blood leukocytes was measured using the quantitative polymerase chain reaction (qPCR).Results: A significant negative correlation was observed between aTL and age in the whole population, among MODY patients and in each subtype studied, MODY2 and MODY3, which allowed us to validate the method. We found, for the first time, that MODY patients have shorter aTL with respect to non‐diabetic controls (6.49 ± 3.31 kbp vs 11.13 ± 7.82 kbp, p = .006). However, no differences were found between MODY2 and MODY3. In addition, aTL showed a negative correlation with duration of the disease and fasting plasma glucose (FPG) levels in MODY patients in general and also with HbA1c in MODY2 patients in particular.Conclusions: Both MODY2 and MODY3 types present telomere shortening, which, at least partly, responds to HbA1c and FPG levels. These findings suggest comparable mechanisms underlying the attrition of TL. Taken together, our results on aTL in MODY patients may provide a parameter relatively easy and inexpensive to quantify in order to measure the impact of high glucose levels and potentially carry out antidiabetic treatment with stricter targets.
- 11 February 2019
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 35 (5) , e3137
Immunological and clinical characteristics of latent autoimmune diabetes in the elderly
Background: Latent autoimmune diabetes in adults (LADA) is determined by both a noninsulin‐dependent clinical presentation and an autoimmune pathogenic process. Glutamic acid decarboxylase antibody (GADA) constitutes the most important marker, although IA‐2A and ZnT8A also define LADA presentation. Type 2 diabetes mellitus (T2DM) is the most prevalent type particularly over 65 years old. Studies about autoimmunity in this age group are scarce.Objective: The aim of this work was to determine whether three autoantibodies for diabetes autoimmunity were present in elderly T2DM patients, and to assess the distinctive clinical features of autoantibody‐positive patients.Research Design and Methods: We recruited 153 patients with diabetes with onset of diabetes after 65 years of age and a BMI under 30 kg/m2.Results: The prevalence of at least one of the autoantibodies was 15.68% (24/153). The most prevalent autoantibody was GADA with 8.49% (13/153), followed by ZnT8A with 6.50% (10/153) and IA2A with 1.96% (3/153). The autoimmunity‐positive group presented higher HbA1c (7.01 ± 1.98 vs 6.35 ± 1.01; P = 0.007) and more prevalent insulin therapy (25% vs 10.85%; P = 0.047). GADA‐positive patients with diabetes presented higher FPG (7.79 ± 3.79 mmol/L vs 6.43 ± 1.6 mmol/L; P = 0.014) and insulin therapy more frequently (46% vs 10.71%; p = 0.015). GADA titre levels in the individuals with BMI under 27 kg/m2 were higher (35.00 ± 4.20) than those in the group with BMI over 27 kg/m2 (8.83 ± 3.041; P = 0.0005).Conclusion: Autoantibodies GADA and Znt8A may be useful markers in identifying a subgroup of older patients with a clinical presentation of diabetes which could be characterized as latent autoimmune diabetes in the elderly.
- 11 February 2019
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 35 (5) , e3137
Immunological and clinical characteristics of latent autoimmune diabetes in the elderly
Background: Latent autoimmune diabetes in adults (LADA) is determined by both a noninsulin‐dependent clinical presentation and an autoimmune pathogenic process. Glutamic acid decarboxylase antibody (GADA) constitutes the most important marker, although IA‐2A and ZnT8A also define LADA presentation. Type 2 diabetes mellitus (T2DM) is the most prevalent type particularly over 65 years old. Studies about autoimmunity in this age group are scarce.Objective: The aim of this work was to determine whether three autoantibodies for diabetes autoimmunity were present in elderly T2DM patients, and to assess the distinctive clinical features of autoantibody‐positive patients.Research Design and Methods: We recruited 153 patients with diabetes with onset of diabetes after 65 years of age and a BMI under 30 kg/m2.Results: The prevalence of at least one of the autoantibodies was 15.68% (24/153). The most prevalent autoantibody was GADA with 8.49% (13/153), followed by ZnT8A with 6.50% (10/153) and IA2A with 1.96% (3/153). The autoimmunity‐positive group presented higher HbA1c (7.01 ± 1.98 vs 6.35 ± 1.01; P = 0.007) and more prevalent insulin therapy (25% vs 10.85%; P = 0.047). GADA‐positive patients with diabetes presented higher FPG (7.79 ± 3.79 mmol/L vs 6.43 ± 1.6 mmol/L; P = 0.014) and insulin therapy more frequently (46% vs 10.71%; p = 0.015). GADA titre levels in the individuals with BMI under 27 kg/m2 were higher (35.00 ± 4.20) than those in the group with BMI over 27 kg/m2 (8.83 ± 3.041; P = 0.0005).Conclusion: Autoantibodies GADA and Znt8A may be useful markers in identifying a subgroup of older patients with a clinical presentation of diabetes which could be characterized as latent autoimmune diabetes in the elderly.
- Open Access
- 22 July 2016
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 8 (1) , 1-10
Challenges associated with insulin therapy progression among patients with type 2 diabetes: Latin American MOSAIc study baseline data
Poor glycemic control in patients with type 2 diabetes is commonly recorded worldwide; Latin America (LA) is not an exception. Barriers to intensifying insulin therapy and which barriers are most likely to negatively impact outcomes are not completely known. The objective was to identify barriers to insulin progression in individuals with type 2 diabetes mellitus (T2DM) in LA countries (Mexico, Brazil, and Argentina). MOSAIc is a multinational, non-interventional, prospective, observational study aiming to identify the patient-, physician-, and healthcare-based factors affecting insulin intensification. Eligible patients were ≥18 years, had T2DM, and were treated with insulin for ≥3 months with/without oral antidiabetic drugs (OADs). Demographic, clinical, and psychosocial data were collected at baseline and regular intervals during the 24-month follow-up period. This paper however, focuses on baseline data analysis. The association between glycated hemoglobin (HbA1c) and selected covariates was assessed. A trend toward a higher level of HbA1c was observed in the LA versus non-LA population (8.40 ± 2.79 versus 8.18 ± 2.28; p ≤ 0.069). Significant differences were observed in clinical parameters, treatment patterns, and patient-reported outcomes in LA compared with the rest of the cohorts and between Mexico, Brazil, and Argentina. Higher number of insulin injections and lower number of OADs were used, whereas a lower level of knowledge and a higher level of diabetes-related distress were reported in LA. Covariates associated with HbA1c levels included age (−0.0129; p < 0.0001), number of OADs (0.0835; p = 0.0264), higher education level (−0.2261; p = 0.0101), healthy diet (−0.0555; p = 0.0083), self-monitoring blood glucose (−0.0512; p = 0.0033), hurried communication style in the process of care (0.1295; p = 0.0208), number of insulin injections (0.1616; p = 0.0088), adherence (−0.1939; p ≤ 0.0104), and not filling insulin prescription due to associated cost (0.2651; p = 0.0198). MOSAIc baseline data showed that insulin intensification in LA is not optimal and identified several conditions that significantly affect attaining appropriate HbA1c values. Tailored public health strategies, including education, should be developed to overcome such barriers. Trial Registration NCT01400971
- 22 July 2016
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 8 (1) , 1-10
Open AccessChallenges associated with insulin therapy progression among patients with type 2 diabetes: Latin American MOSAIc study baseline data
Poor glycemic control in patients with type 2 diabetes is commonly recorded worldwide; Latin America (LA) is not an exception. Barriers to intensifying insulin therapy and which barriers are most likely to negatively impact outcomes are not completely known. The objective was to identify barriers to insulin progression in individuals with type 2 diabetes mellitus (T2DM) in LA countries (Mexico, Brazil, and Argentina). MOSAIc is a multinational, non-interventional, prospective, observational study aiming to identify the patient-, physician-, and healthcare-based factors affecting insulin intensification. Eligible patients were ≥18 years, had T2DM, and were treated with insulin for ≥3 months with/without oral antidiabetic drugs (OADs). Demographic, clinical, and psychosocial data were collected at baseline and regular intervals during the 24-month follow-up period. This paper however, focuses on baseline data analysis. The association between glycated hemoglobin (HbA1c) and selected covariates was assessed. A trend toward a higher level of HbA1c was observed in the LA versus non-LA population (8.40 ± 2.79 versus 8.18 ± 2.28; p ≤ 0.069). Significant differences were observed in clinical parameters, treatment patterns, and patient-reported outcomes in LA compared with the rest of the cohorts and between Mexico, Brazil, and Argentina. Higher number of insulin injections and lower number of OADs were used, whereas a lower level of knowledge and a higher level of diabetes-related distress were reported in LA. Covariates associated with HbA1c levels included age (−0.0129; p < 0.0001), number of OADs (0.0835; p = 0.0264), higher education level (−0.2261; p = 0.0101), healthy diet (−0.0555; p = 0.0083), self-monitoring blood glucose (−0.0512; p = 0.0033), hurried communication style in the process of care (0.1295; p = 0.0208), number of insulin injections (0.1616; p = 0.0088), adherence (−0.1939; p ≤ 0.0104), and not filling insulin prescription due to associated cost (0.2651; p = 0.0198). MOSAIc baseline data showed that insulin intensification in LA is not optimal and identified several conditions that significantly affect attaining appropriate HbA1c values. Tailored public health strategies, including education, should be developed to overcome such barriers. Trial Registration NCT01400971
- Open Access
- 1 January 2016
- Published by Elsevier in Revista Argentina de Endocrinologia Y Metabolismo
- Vol. 53 (1) , 22-28
Análisis de la longitud de los telómeros en obesos metabólicamente sanos
- 1 January 2016
- Published by Elsevier in Revista Argentina de Endocrinologia Y Metabolismo
- Vol. 53 (1) , 22-28
Open AccessAnálisis de la longitud de los telómeros en obesos metabólicamente sanos
- 12 January 2007
- Published by Elsevier in Molecular and Cellular Probes
- Vol. 21 (3) , 222-225
A simple method for the identification of three major haplotypes of the β2AR
- 12 January 2007
- Published by Elsevier in Molecular and Cellular Probes
- Vol. 21 (3) , 222-225
A simple method for the identification of three major haplotypes of the β2AR